Angiogenesis inhibitor
agent and endogenous substance that antagonizes or inhibits the development of new blood vessels
An angiogenesis inhibitor is a substance that inhibits the growth of new blood vessels (angiogenesis). Some angiogenesis inhibitors are endogenous and a normal part of the body's control and others are obtained exogenously through pharmaceutical drugs or diet.
While angiogenesis is a critical part of wound healing and other favorable processes, certain types of angiogenesis are associated with the growth of malignant tumors. Thus angiogenesis inhibitors have been closely studied for possible cancer treatment. Angiogenesis inhibitors were once thought to have potential as a "silver bullet" treatment applicable to many types of cancer, but the limitations of anti-angiogenic therapy have been shown in practice. Currently, angiogenesis inhibitors are recognized for their improvement of cancer immunotherapy by overcoming endothelial cell anergy. Angiogenesis inhibitors are also used to effectively treat macular degeneration in the eye, and other diseases that involve a proliferation of blood vessels.
Mechanism of action
When a tumor stimulates the growth of new vessels, it is said to have undergone an 'angiogenic switch'. The principal stimulus for this angiogenic switch appears to be oxygen deprivation, although other stimuli such as inflammation, oncogenic mutations and mechanical stress may also play a role. The angiogenic switch leads to tumor expression of pro-angiogenic factors and increased tumor vascularization.
“Angiogenesis inhibitor” enters the record as agent and endogenous substance that antagonizes or inhibits the development of new blood vessels. Crown Archives preserves that source wording while asking what Angiogenesis, inhibitor and agent can confirm, complicate or overturn.
Why this record matters
“Angiogenesis inhibitor” is worth following because a concise public description often conceals a longer documentary argument. Here, Angiogenesis, inhibitor and agent provides the most credible route into that argument.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Jul 16, 2026. The linked authority identifier is Q574834. None of the 0 selected statements returned an explicit reference.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Angiogenesis inhibitor”, its source revision and the description used here.
- Expand the search: follow Angiogenesis inhibitor primary sources, Angiogenesis inhibitor archive and Angiogenesis research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Angiogenesis inhibitor”?
- Which cited source is closest to the event, object or claim?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Angiogenesis inhibitor” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.